Biotech crossover in­vestor Fore­site is lin­ing up a $650M stake for the big gam­bles to come

Biotech in­vestor Fore­site Cap­i­tal is lin­ing up a new fund, and this time it’s go­ing big.

In a new SEC fil­ing post­ed Thurs­day, Fore­site alert­ed the in­dus­try that it is lin­ing up a $650 mil­lion suc­ces­sor to the $450 mil­lion Fund III that got start­ed two years ago.

Fore­site is a very fa­mil­iar if fair­ly low-key play­er in the biotech world; a crossover in­vestor that has kept friend­ly ties in place with syn­di­cates that of­ten in­clude cagey play­ers like RA Cap­i­tal, which en­joys noth­ing as much as look­ing for some fast re­turns — say a year out — through go-go mar­kets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.